SCHEMBL2322849

SCHEMBL2322849

Cc1ccccc1-c1cc2c(nn1)C1CCC2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
ALDH1A1 P00352 4/20 0.43
NPC1 O15118 3/20 0.43
MAPT P10636 3/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
APAF1 O14727 1/20 0.43
TDP2 O95551 1/20 0.43
LMNA P02545 1/20 0.43
PKM P14618 1/20 0.43
MAOB P27338 1/20 0.43
HTT P42858 1/20 0.43
CNR2 P34972 1/20 0.36
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2326805 0.89 CNR2 (0.39) RAB9ASMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL2321830 0.84 LMNA (0.37) MAPTLMNA
SCHEMBL2323614 0.82 NPC1 (0.36) RAB9ASMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL2326588 0.82 HPGD (0.45) RAB9ASMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL2325997 0.82 NOTUM (0.38)
SCHEMBL2321845 0.82 CYP11B1 (0.39) CYP3A4
SCHEMBL2325632 0.79 TRPA1 (0.43) MEN1KMT2ACNR2CYP1A2CYP2D6
SCHEMBL2325609 0.77 CNR2 (0.44) CNR2IDO1
SCHEMBL2321655 0.76 CNR2 (0.43) MAPTKDM4ECNR2POLB
SCHEMBL2327315 0.76 GRM4 (0.39) RAB9ASMN1; SMN2ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP claimed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US claimed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 RAB9A 3579/4885SMN1; SMN2 2843/4885ALDH1A1 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.